Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

NCT05294731 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancy
Non-Hodgkin Lymphoma
Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Waldenström Macroglobulinemia
Marginal Zone Lymphoma
Follicular Lymphoma
DLBCL Unclassifiable
Richter's Transformation

Interventions

DRUG: BGB-16673

Sponsor

BeiGene